Illumina, Inc. (ILMN)
| Market Cap | 20.56B |
| Revenue (ttm) | 4.34B |
| Net Income (ttm) | 850.00M |
| Shares Out | 152.90M |
| EPS (ttm) | 5.45 |
| PE Ratio | 24.67 |
| Forward PE | 26.20 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,008,460 |
| Open | 127.97 |
| Previous Close | 127.40 |
| Day's Range | 127.00 - 134.76 |
| 52-Week Range | 68.70 - 155.53 |
| Beta | 1.45 |
| Analysts | Hold |
| Price Target | 124.24 (-7.6%) |
| Earnings Date | Feb 5, 2026 |
About ILMN
Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for ILMN stock is "Hold." The 12-month stock price target is $124.24, which is a decrease of -7.60% from the latest price.
News
Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida
Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NA...
Takara Bio USA, Inc. Collaborates with Illumina on Spatial Transcriptomics Workflow, Details Presented at AGBT 2026
SAN JOSE, Calif.--(BUSINESS WIRE)-- #NGS--Takara Bio USA collaborates with Illumina on a single-cell-resolution spatial mapping workflow, presented at AGBT 2026.
Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics
At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutions SAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer bre...
Illumina launches TruPath Genome, setting a new standard in genomic insight
TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow Data presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic disease Broad Clinic...
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility
40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaS eq X systems , advancing precis...
Illumina To Webcast Upcoming Investor Conference
SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference: Upcoming Investor Conf...
Invesco International Growth Fund Q4 2025 Portfolio Update
Invesco International Growth Fund underperformed most in industrials, consumer discretionary and communication services, all due to stock selection. We initiated five positions during the quarter, fou...
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Illumina, Inc. (ILMN) Q4 2025 Earnings Call Transcript
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
Fourth quarter 2025 results: Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis) Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis...
Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally
Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samples Sequencing connects decades of preserved biodiversity wit...
Illumina completes acquisition of SomaLogic
Deeply expands leadership in proteomics and multiomics Combined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina'...
Illumina Gets Medicare Boost for Cancer Test, Shares Climb
Illumina Inc. (NASDAQ: ILMN) shares are up on Tuesday following news that the company has secured reimbursement for its FDA-approved TruSight Oncology Comprehensive test.
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/ ...
GRAIL Inc. - Illumina's Divested Holy Grail
GRAIL (GRAL) offers MCED screening tests that offer employers economic value and employee health clarity. Divestiture of GRAIL by Illumina offers investors $8B valuation foundation. TAM valuation impl...
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Illumina unveils dataset to speed up AI-powered drug discovery
Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence.
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the wor...
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025...
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, Fe...
Illumina Appoints Dr. Eric Green as Chief Medical Officer
Veteran genomics leader joins Illumina to advance global medical strategy Illumina chief commercial officer to depart for role as a life science tools company CEO SAN DIEGO, Jan. 8, 2026 /PRNewswire/...
Illumina and PREMIA partner to expand clinical access to CGP in Asia
TAIPEI, Taiwan, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Illumina Taiwan Biotechnology Co., Ltd., and Precision Medicine Asia, Limited (PREMIA), a leading Asian cancer clinical-genomic screening network, tod...
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis
Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: I...
Santa Rally Looms: These 5 Stocks Often Deliver Gifts To Investors
Year-end trading on Wall Street follows a familiar pattern, and the same question resurfaces once again: will the Santa Claus rally make an appearance?
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually
Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PA...
Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript
Illumina, Inc. ( ILMN) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel ...